BMS-986094

Phase 2Small molecule

Bristol-Myers Squibb

BMS-986094 is one of 62 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatitis CActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Hepatitis CPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

BMS-986094

Bristol-Myers Squibb

Phase 2

1 10

SOF/VEL

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis1 trial

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01629732

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BMS-986094. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986094 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986094. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986094

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis1 trial

References

Drug Info

Quick Facts

Related News